Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

NCT03699449 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT03699449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03699449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Unknown status
Start date
November 26, 2018
Completion date
September 30, 2022
Enrollment
104 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant recurrent ovarian cancer